Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.

Conroy, Samantha; Pang, Karl; Jubber, Ibrahim; Hussain, Syed A; Rosario, Derek J; Cumberbatch, Marcus G; Catto, James W F; Noon, Aidan P

Conroy, Samantha; Pang, Karl; Jubber, Ibrahim; Hussain, Syed A; Rosario, Derek J; Cumberbatch, Marcus G; Catto, James W F; Noon, Aidan P.

Afiliação

Conroy S; Academic Urology Unit, Department of Oncology and Metabolism University of Sheffield Sheffield UK.
Pang K; Department of Urology Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK.
Jubber I; Academic Urology Unit, Department of Oncology and Metabolism University of Sheffield Sheffield UK.
Hussain SA; Academic Urology Unit, Department of Oncology and Metabolism University of Sheffield Sheffield UK.
Rosario DJ; Department of Urology Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK.
Cumberbatch MG; Academic Oncology Unit, Department of Oncology and Metabolism University of Sheffield Sheffield UK.
Catto JWF; Department of Urology Sheffield Teaching Hospitals NHS Foundation Trust Sheffield UK.
Noon AP; Academic Urology Unit, Department of Oncology and Metabolism University of Sheffield Sheffield UK.

BJUI Compass ; 4(3): 314-321, 2023 May.

Article em En | MEDLINE | ID: mdl-37025474

Palavras-chave

acceptability; high risk; hyperthermic intravesical chemotherapy; intravesical treatment; mitomycin C; nonmuscleinvasive bladder cancer; tolerability

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Observational_studies / Risk_factors_studies Idioma: En Revista: BJUI Compass Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google